Skip to main content

Cystic fibrosis: how could gene and cell therapy help?

Cystic fibrosis is one of the most common genetic diseases. It is associated with chronic lung disease, as well as damage to other organs. It arises from mutations in a single gene: the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Some forms of CF can be treated using modulator therapies; however, because the disease can be caused by different mutations, these therapies are not suitable for all forms of the disease. Can gene and cell therapy techniques help us to understand and treat CF more effectively?

Introduction to Cystic Fibrosis

The lining of the airways in the lungs is made up of different types of epithelial cells. Many of these cells contribute to maintaining the composition of the thin layer of sticky fluid (mucus) that covers the airways. This mucus helps protect the lung from potentially infectious micro-organisms in the inhaled air, such as bacteria and viruses. It also lubricates the lungs, protecting the tissue from damage.

Cystic fibrosis (CF) is characterised by abnormal functioning of these epithelial secretory cells. At a cellular level, the mechanism for transporting water and salts into and out of the cells does not work. This affects the thickness of the mucus produced by the pulmonary (lung) epithelium. This abnormal mucus cannot adequately keep bacteria under control, leading to persistent infection. The most serious symptom, that has the biggest impact on quality of life, is the thick mucus secretions that build up in the lungs leading to infections and lung damage and result in a progressive decrease in lung function leading to breathing difficulties and periods of acute lung infection that often require hospitalisation.

The lungs are not the only organ system affected by CF. At a cellular level, CF is characterised by abnormal transport of ions such as salts in the epithelial secretory cells of many organs. This means that the cells cannot move water in and out the way healthy cells do. One consequence of this is that people with CF have unusually high amounts of salt within their sweat; this has been used as a diagnostic tool for many years. Additionally, the thickness of the mucus secretions in the gastrointestinal tract, reproductive tract, liver, and pancreas are all affected.

CF frequency varies with ethnicity and is significantly more common in Caucasian populations. In the USA for example, CF occurs in 1 in 2,500 to 3,500 white newborns, similar to that observed in European populations. It is less common in other ethnic groups, estimated to affect about 1 in 4,000 – 10,000 Latin Americans, 1 in 17,000 African Americans and 1 in 31,000 Asian Americans.

Current treatments

There have been significant improvements in therapy for CF over the years. Historically, treatment has focused on controlling symptoms, rather than on treating the underlying cause of the disease. This changed with the recent development of modulator therapies – therapies which target the fault membrane channel. With these therapeutic advances, the majority of people with CF have a greatly improved quality of life and are living longer than ever before. 

How might gene and cell therapies help?

Gene therapies

Genetic therapies have the potential to help people with CF by:

  • adding a working copy of the gene to cells to make up for the faulty gene through conventional gene therapy
  • delivering mRNA that can act as a CFTR-protein making template
  • directly changing the error in the faulty gene back to the correct sequence, through gene editing.

The advantage of gene therapy is that it can benefit all people with CF no matter what their mutation type might be. If the correct gene can be delivered in enough cells then this can restore the correct movement of salt and water and prevent the accumulation of the thick sticky mucus. The main focus of this type of research has been the cells lining the lung. This is where the effects of the disease have the biggest impact of quality of life and survival.

Most gene therapy approaches to treat CF involve delivering a healthy copy of the CFTR gene directly to the affected cells. There are a number of different approaches. All of them require a way of getting the DNA into a sufficient number of cells.

To do this requires something to carry the DNA into the cell (a vector). Some vectors are made from inactivated viruses; and some of them are a form of non-viral nanoparticles (often made of lipid/protein components, which bind to DNA and target cells).

Several additional approaches are being investigated in the laboratory, and are progressing towards clinical trial. One of these, (from Spirovant) uses an AAV vector; one (from Carbon Biosciences) uses a hybrid AAV; and two (from Boehringer Ingelheim and Spirovant) use lentiviral vectors. The significant difference with the lentiviral vectors is that the DNA is inserted into the host cell DNA. This means that the effect is expected to be longer-lasting.

Since lentiviral vectors integrate into the host chromosomes, this has raised some safety concerns. Scientists must consider the possibility of adverse effects on other genes close to the integration site. The design of these lentiviral vectors has evolved over the years to  greatly reduce this risk. These are termed self-inactivating (SIN) vectors. This type of lentiviral vector has been extensively used in therapies for other disease indications, in particular in the generation of CAR-T cells for blood cancers. To date, there have been no reported serious adverse events. However, as these are new therapies, researchers are required to continue conducting long-term follow-up in treated patients to monitor for adverse events.

Several organisations have therapies in the advanced stages of preclinical development. These include Boehring Ingelheim and the UK Respiratory Gene Therapy Consortium (BI 3720931, a lentiviral vector), Spirovant (SP-101, an AAV vector, and SP-102, a lentiviral vector), and Carbon Biosciences (a hybrid viral vector).

mRNA therapies

Another approach is to deliver ‘messenger RNA’ (mRNA) instead of DNA. mRNA is the rather short-lived ‘template’ produced from DNA; the cell then uses this template to produce the protein coded by the gene. In mRNA-based therapy, this genetic material does not need to get to the nucleus and therefore never integrates into the host’s own genetic material. This also means that the delivered mRNA will only persist for a short time in the cell and would require regular re-administration. However, it has the potential advantage of not containing any components that may induce an immune response. Researchers are currently (in July 2024) recruiting participants for a Phase 1 clinical trial, to confirm the safety of this approach. (This trial is being conducted by Vertex/Moderna, examining the safety of the product VX-522.)

Another promising therapeutic approach for CF is full-length CFTR mRNA replacement: that is, inserting a complete mRNA template of a healthy CFTR gene. This should work regardless of the particular mutation carried by the patient. 

Clinical trials for mRNA therapies

Three early-phase clinical trials of inhaled mRNA therapy for CF (CFTR mRNA encapsulated in a lipid nanoparticle) are in progress currently (2024). The three products being tested are:

 1) RCT2100, in healthy volunteers

2) ARCT-032, in healthy volunteers and adults with CF

3) VX-522 in adults with CF who are ineligible for CFTR modulator therapy.

Gene editing

Gene editing is a very precise technology. Rather than inserting a new gene, it involves correcting the mutation in the patient’s own faulty gene. A Strategic Research Centre, co-funded by the CF Trust (UK) and the CF Foundation (US) are working to develop gene editing tools for CF. As well as researching how the genes can be edited and corrected, this SRC is considering different approaches for how to treat patients:

  • Coating ‘gene editing molecules’ in nanoparticles, which could then be inhaled into the lungs as an aerosol.
  • Collecting cells from the patients, editing them in the lab to correct the mutation, growing up large numbers of these ‘corrected’ cells, and then transplanting them back into the patients.

So far, this work is all in the early preclinical development stage. This involves evaluation in animal models. Much more time and effort will be required to confirm whether these approaches are feasible, effective, and safe for use in humans.

Stem cells and disease modelling

Stem cells can play an important role in understanding CF. Researchers are currently collecting cells from patients with different CFTR mutations and converting them into a form of stem cell called induced pluripotent stem cells (iPSCs). These cells can be grown into different types of lung cells in the lab. This allows researchers to study how each CFTR mutation affects the cells of the lung and to understand the mechanisms by which different mutations act. 

These cells can also be used to develop disease models, allowing scientists to test new therapies and drugs. Testing on cells derived from different individuals means that scientists can gain a broader understanding of how different individuals may respond to a therapy. This means researchers have a more balanced view of the potential effects before they apply the therapy to trial participants. Cell therapies

Scientists are also exploring using tissue engineering techniques to develop lung grafts from stem cells for patients with CF.  Like the techniques above, this would involve collecting lung cells from patients living with CF to generate patient-specific stem cells. These cells would have the mutation corrected in the lab before being grown in large numbers and used to generate healthy lung tissue. This tissue could potentially be used as a graft to replace severely damaged lung tissue. This research is in the very early stages, and it will take several years of pre-clinical work to confirm whether this approach may be viable.

Find out more

The Cystic Fibrosis Trust provides information for patients and carers about CF, including information about ongoing research.

The Strategic Research Centre for CF is a group of UK-based researchers collaborating to develop personalised cell therapies for cyistic fibrosis.

The UK Respiratory Gene Therapy Consortium is conducting researching into gene therapy-based approaches to CF.

Related pages

Did you find the content on this page useful? If not, you can leave us a message so we can improve Send us your thoughts